232 related articles for article (PubMed ID: 32991011)
21. Solute carrier family 16 member 5 downregulation and its methylation might serve as a prognostic indicator of prostate cancer.
Meng X; Yuan H; Li W; Xiong Z; Dong W; Xiao W; Zhang X
IUBMB Life; 2021 Nov; 73(11):1363-1377. PubMed ID: 34549875
[TBL] [Abstract][Full Text] [Related]
22. RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
Strand SH; Switnicki M; Moller M; Haldrup C; Storebjerg TM; Hedegaard J; Nordentoft I; Hoyer S; Borre M; Pedersen JS; Wild PJ; Park JY; Orntoft TF; Sorensen KD
Oncotarget; 2017 Jan; 8(4):5774-5788. PubMed ID: 28052017
[TBL] [Abstract][Full Text] [Related]
23. Association of DSC3 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
Pan J; Chen Y; Mo C; Wang D; Chen J; Mao X; Guo S; Zhuang J; Qiu S
PLoS One; 2014; 9(3):e92815. PubMed ID: 24664224
[TBL] [Abstract][Full Text] [Related]
24. MTSS1 hypermethylation is associated with prostate cancer progression.
Chen J; Huang L; Zhu Q; Wang Z; Tang Z
J Cell Physiol; 2020 Mar; 235(3):2687-2697. PubMed ID: 31541465
[TBL] [Abstract][Full Text] [Related]
25. Methylation and transcriptome analysis reveal lung adenocarcinoma-specific diagnostic biomarkers.
Li R; Yang YE; Yin YH; Zhang MY; Li H; Qu YQ
J Transl Med; 2019 Sep; 17(1):324. PubMed ID: 31558162
[TBL] [Abstract][Full Text] [Related]
26. Identification of new differentially methylated genes that have potential functional consequences in prostate cancer.
Kim JW; Kim ST; Turner AR; Young T; Smith S; Liu W; Lindberg J; Egevad L; Gronberg H; Isaacs WB; Xu J
PLoS One; 2012; 7(10):e48455. PubMed ID: 23119026
[TBL] [Abstract][Full Text] [Related]
27.
Holmes EE; Goltz D; Sailer V; Jung M; Meller S; Uhl B; Dietrich J; Röhler M; Ellinger J; Kristiansen G; Dietrich D
Clin Epigenetics; 2016; 8():104. PubMed ID: 27708722
[TBL] [Abstract][Full Text] [Related]
28. Integrative analysis of DNA methylation and gene expression to identify key epigenetic genes in glioblastoma.
Jia D; Lin W; Tang H; Cheng Y; Xu K; He Y; Geng W; Dai Q
Aging (Albany NY); 2019 Aug; 11(15):5579-5592. PubMed ID: 31395792
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
[TBL] [Abstract][Full Text] [Related]
30. The investigation of GSTP1, APC and RASSF1 gene promoter hypermethylation in urine DNA of prostate-diseased patients.
Haluskova J; Lachvac L; Nagy V
Bratisl Lek Listy; 2015; 116(2):79-82. PubMed ID: 25665470
[TBL] [Abstract][Full Text] [Related]
31. Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.
Kamdar S; Isserlin R; Van der Kwast T; Zlotta AR; Bader GD; Fleshner NE; Bapat B
Clin Epigenetics; 2019 Mar; 11(1):54. PubMed ID: 30917865
[TBL] [Abstract][Full Text] [Related]
32. Epigenome-wide DNA methylation and transcriptome profiling of localized and locally advanced prostate cancer: Uncovering new molecular markers.
Liu Q; Reed M; Zhu H; Cheng Y; Almeida J; Fruhbeck G; Ribeiro R; Hu P
Genomics; 2022 Sep; 114(5):110474. PubMed ID: 36057424
[TBL] [Abstract][Full Text] [Related]
33. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
[TBL] [Abstract][Full Text] [Related]
34. Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma.
Zhang D; Zhang M; Zhang Q; Zhao Z; Nie Y
Med Sci Monit; 2020 Jul; 26():e924543. PubMed ID: 32735556
[TBL] [Abstract][Full Text] [Related]
35. Comparative analysis of epi-miRNA expression levels in local/locally advanced and metastatic prostate cancer patients.
Gurbuz V; Kiliccioglu I; Dikmen AU; Bilen CY; Sozen S; Konac E
Gene; 2020 Oct; 758():144963. PubMed ID: 32683077
[TBL] [Abstract][Full Text] [Related]
36. A four-gene signature associated with clinical features can better predict prognosis in prostate cancer.
Yuan P; Ling L; Fan Q; Gao X; Sun T; Miao J; Yuan X; Liu J; Liu B
Cancer Med; 2020 Nov; 9(21):8202-8215. PubMed ID: 32924329
[TBL] [Abstract][Full Text] [Related]
37. High expression of nucleobindin 2 mRNA: an independent prognostic factor for overall survival of patients with prostate cancer.
Zhang H; Qi C; Wang A; Li L; Xu Y
Tumour Biol; 2014 Mar; 35(3):2025-8. PubMed ID: 24092574
[TBL] [Abstract][Full Text] [Related]
38. MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors.
Torres-Ferreira J; Ramalho-Carvalho J; Gomez A; Menezes FD; Freitas R; Oliveira J; Antunes L; Bento MJ; Esteller M; Henrique R; Jerónimo C
Mol Cancer; 2017 Jan; 16(1):26. PubMed ID: 28143614
[TBL] [Abstract][Full Text] [Related]
39. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
[TBL] [Abstract][Full Text] [Related]
40. Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients.
Moreira-Barbosa C; Barros-Silva D; Costa-Pinheiro P; Torres-Ferreira J; Constâncio V; Freitas R; Oliveira J; Antunes L; Henrique R; Jerónimo C
Clin Epigenetics; 2018 Oct; 10(1):132. PubMed ID: 30373654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
